research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
Search
for
Sort by
Research
600-630 / 1000+ results
research Fractional‐assisted drug delivery performed with erbium yag laser in androgenic alopecia: Histological aspects
Channels stay open for 24 hours, making laser treatment potentially effective for hair loss.
research Primary Vitreoretinal Lymphoma Presenting Solely with Asymptomatic Peripheral Drusenoid Lesions
Older patients with new retinal lesions may have cancer, and local radiation might not stop it from spreading.
research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata
Ritlecitinib works well and is safe for treating alopecia areata.
research Diagnosis dan Penanganan TB-IRIS Paradoksikal
Early detection, prevention, and proper management can reduce TB-IRIS complications and deaths in HIV patients.
research EXPERIENCE WITH ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH NEUROLOGICAL MANIFESTATIONS
Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
research Comorbilidades asociadas a alopecia areata, un estudio retrospectivo en un centro dermatológico de Bogotá
Alopecia areata often appears on the scalp and is linked to various health issues, needing thorough evaluation.
research A Randomized Double-Blind Evaluation of a Novel Biotin and Silicon Ingredient Complex on the Hair and Skin of Healthy Women
LustrivaTM improves hair thickness and reduces facial wrinkles safely.
research RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia.
RUM-loaded SLN shows promise for treating acne and hair loss topically.
research 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research 070 Bacillary Load and Reactional States in Leprosy - A Surge in Severity the COVID Era?
The COVID-19 pandemic has led to more severe cases of Leprosy due to delayed medical care.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Efficacy of Rituximab in Successful Management of Refractory Juvenile Systemic Lupus Erythematosus Complicated with Macrophage Activation Syndrome: A Case Report with Literature Overview
Rituximab effectively managed a difficult case of juvenile lupus with complications, reducing the need for steroids.
research VISIA Skin Analysis System as a Tool to Evaluate the Reduction of Pigmented Skin and Vascular Lesions Using the 532 Nm Laser
The 532 nm laser effectively reduces facial vascular and pigmented lesions, with the VISIA system reliably assessing treatment results.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Post severe COVID-19 infection lung damages study. The experience of early three months multidisciplinary follow-up
After severe COVID-19, lung damage can improve, detected effectively by lung-ultrasound, and high pressure support during hospitalization can increase lung artery size. Also, about 22% of patients had lung blood clots, and when treated, they recovered faster.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Albendazole-induced anagen effluvium
A woman experienced rapid hair loss after taking albendazole, but it started to improve when she stopped the medication.
research Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa
Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
research Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
Infectious virus was not found after the third remdesivir dose, suggesting early end of isolation is possible.
research Bibliometric analysis and visualization of research trends on HIV-1 capsid inhibitors (2000–2022)
Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.
research Back cover
A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.
research Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research 62339 Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
research New food supplement cures alopecia
A new food supplement was highly effective in curing hair loss in young men.
research Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry
The method effectively measures drug impact on DHT levels in prostate treatments.